These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 30762274)

  • 1. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
    Goll GL; Jørgensen KK; Sexton J; Olsen IC; Bolstad N; Haavardsholm EA; Lundin KEA; Tveit KS; Lorentzen M; Berset IP; Fevang BTS; Kalstad S; Ryggen K; Warren DJ; Klaasen RA; Asak Ø; Baigh S; Blomgren IM; Brenna Ø; Bruun TJ; Dvergsnes K; Frigstad SO; Hansen IM; Hatten ISH; Huppertz-Hauss G; Henriksen M; Hoie SS; Krogh J; Midtgard IP; Mielnik P; Moum B; Noraberg G; Poyan A; Prestegård U; Rashid HU; Strand EK; Skjetne K; Seeberg KA; Torp R; Ystrøm CM; Vold C; Zettel CC; Waksvik K; Gulbrandsen B; Hagfors J; Mørk C; Jahnsen J; Kvien TK
    J Intern Med; 2019 Jun; 285(6):653-669. PubMed ID: 30762274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Jørgensen KK; Olsen IC; Goll GL; Lorentzen M; Bolstad N; Haavardsholm EA; Lundin KEA; Mørk C; Jahnsen J; Kvien TK;
    Lancet; 2017 Jun; 389(10086):2304-2316. PubMed ID: 28502609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
    Jørgensen KK; Goll GL; Sexton J; Bolstad N; Olsen IC; Asak Ø; Berset IP; Blomgren IM; Dvergsnes K; Florholmen J; Frigstad SO; Henriksen M; Hagfors J; Huppertz-Hauss G; Haavardsholm EA; Klaasen RA; Moum B; Noraberg G; Prestegård U; Rydning JH; Sagatun L; Seeberg KA; Torp R; Vold C; Warren DJ; Ystrøm CM; Lundin KEA; Kvien T; Jahnsen J
    BioDrugs; 2020 Oct; 34(5):681-694. PubMed ID: 32965617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
    Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
    Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
    Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
    Bronswijk M; Moens A; Lenfant M; Tops S; Compernolle G; Van Assche G; Vermeire S; Gils A; Ferrante M
    Inflamm Bowel Dis; 2020 Mar; 26(4):628-634. PubMed ID: 31400283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
    Park W; Yoo DH; Miranda P; Brzosko M; Wiland P; Gutierrez-Ureña S; Mikazane H; Lee YA; Smiyan S; Lim MJ; Kadinov V; Abud-Mendoza C; Kim H; Lee SJ; Bae Y; Kim S; Braun J
    Ann Rheum Dis; 2017 Feb; 76(2):346-354. PubMed ID: 27117698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
    Mahmmod S; Schultheiss JPD; van Bodegraven AA; Dijkstra G; Gilissen LPL; Hoentjen F; Lutgens MWMD; Mahmmod N; van der Meulen-de Jong AE; Smits LJT; Tan ACITL; Oldenburg B; Fidder HH
    Inflamm Bowel Dis; 2021 Nov; 27(12):1954-1962. PubMed ID: 33538298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
    Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.
    Martín-Gutiérrez N; Sánchez-Hernández JG; Rebollo N; Pordomingo AF; Muñoz F; Otero MJ
    Eur J Hosp Pharm; 2022 Jul; 29(4):222-227. PubMed ID: 33115797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
    Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
    Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.